Developer docs
API playgroundTry for free, no card

Search company profiles

Schrödinger

Full company profile

uuid0000lh4

Namestring
Schrödinger
Legal namestring
Schrödinger, Inc.
Websiteurl
schrodinger.com
Company typeenum
Public
Founded yearint
1990
Descriptiontext

Schr\u00f6dinger (NASDAQ:SDGR) is a computational molecular discovery software company founded in 1990 and headquartered in New York, with approximately 800 employees across 15 global locations. The company operates a dual business model. First, it licenses a physics-based computational platform that combines quantum mechanics (Jaguar), molecular dynamics (Desmond), molecular docking (Glide), free energy perturbation (FEP+), and proprietary force fields (OPLS4/OPLS3e) with machine learning capabilities (DeepAutoQSAR, LiveDesign ML, generative De Novo Design). The platform is delivered through Maestro (the GUI) and LiveDesign (enterprise informatics), and is transitioning from on-premise licensing to hosted cloud subscriptions with a target of 75% hosted mix within three years. Second, the company pursues co-founded drug discovery programs and strategic collaborations with major pharmaceutical companies, holding equity stakes in entities including Nimbus Therapeutics, Morphic Therapeutic (acquired by Lilly 2024), Ajax Therapeutics (acquired by Lilly 2026 for up to $2.3 billion), Structure Therapeutics, and Copernic Catalysts.

The platform serves three primary customer segments: pharmaceutical and biotechnology companies (the dominant segment with names including Eli Lilly, Novartis, Bristol Myers Squibb, Takeda, and Otsuka), academic research institutions, and materials science companies (specialty chemicals, electronics, energy). FY2025 total revenue was $255.9 million, with software revenue of $199.5 million (+10.6% YoY) and drug discovery revenue of $56.4 million (more than doubled YoY). The software business sells through direct enterprise field sales with annual contract value (ACV) as the key metric; 2026 software ACV guidance is $218-228 million, implying 10-15% growth. Drug discovery revenue flows from milestone and royalty payments on partnered programs, with cumulative potential milestone exposure estimated at approximately $5 billion across the collaboration portfolio.

The company's proprietary clinical pipeline includes SGR-1505 (MALT1 inhibitor with FDA Fast Track and Orphan Drug Designations for B-cell malignancies, Phase 1) and SGR-3515 (Wee1/Myt1 dual kinase inhibitor for solid tumors, Phase 1). Recent strategic moves include a multi-target Novartis collaboration worth up to $2.3 billion in potential milestones (2025), integration of Eli Lilly's TuneLab AI platform into LiveDesign (January 2026), a multi-year platform agreement with AI-native biotech Manas AI (January 2026), adoption of NVIDIA's BioNeMo Agent Toolkit (June 2026), and the planned summer 2026 launch of Bunsen, an agentic AI co-scientist system. As of January 2026, the company's valuation was approximately $4.74 billion with $402.3 million in cash and equivalents at year-end 2025.

Short descriptiontext

Schr\u00f6dinger provides a physics-based computational molecular discovery platform combining quantum mechanics, molecular dynamics, and machine learning to accelerate drug discovery and materials science for pharmaceutical, biotechnology, academic, and materials industry customers, supplemented by equity stakes in co-founded therapeutic programs.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
501–1,000
akta.pro rankint
HeadquartersNew York, United States
HQ citystring
New York
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
computational drug discovery, molecular simulation software, pharmaceutical research platforms, materials science modeling, quantum chemistry software
Industry4 codes
PRIMARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAIALAA
Drug Discovery (Target ID/Validation & Hit Discovery)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHDAGAEAB
Pharmaceutical & Biotech R&D Simulation (drug discovery, protein/ligand)
Hardware, Technology & Telecom/Quantum Computing/Quantum Simulation & Digital Twins
SECONDARYHLAAAIAL
Library & Diversity Generation Platforms (display libraries, DNA-encoded libraries for biologics, variant libraries)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code3 codes
  • Software Publishers5132
  • Scientific Research and Development Services5417
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • Services-Commercial Physical & Biological Research8731
  • Pharmaceutical Preparations2834
Product category
Computational Drug Discovery Software
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Software Licensing
TypeSubscription Recurring
Description

Recurring software licenses for computational molecular discovery platform. Schrödinger is transitioning from on-premise to hosted (cloud-based) software licensing model, targeting 75% migration within three years. Software revenue was $199.5 million in FY2025, growing 10.6% year-over-year.

stocktitan.net
2Drug Discovery Collaborations
TypeLicensing Royalties
Description

Milestone payments and collaboration revenue from drug discovery programs. Drug discovery revenue doubled to $56.4 million in FY2025. Includes partnerships with Lilly, Novartis, Bristol Myers Squibb, Otsuka, and others, with potential milestones up to $5 billion cumulative across portfolio.

pharmiweb.com
3Strategic Collaborations - Novartis
TypeLicensing Royalties
Description

$150 million upfront payment from Novartis for multi-target research collaboration with up to $2.3 billion in potential milestone payments

matrixbcg.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Marketing or Sales, Operations, Infrastructure
Pricing details1 tier
1Hosted software licensing (primary model)
ModelSubscriptionBilling cadenceAnnual
Notes

Transitioning to hosted model; ACV guidance for 2026 is $218-228 million representing 10-15% growth

finance.yahoo.com
GTM typeB2B
B2B
Offering typeSoftware
Software
Core offering1 text field

Schrödinger develops and licenses a physics-based computational molecular discovery platform combining quantum mechanics, molecular dynamics, and machine learning to accelerate drug discovery and materials science research. The platform centers on Maestro as the user interface, with computational engines including Glide (docking), FEP+ (free energy perturbation), Desmond (molecular dynamics), and Jaguar (quantum mechanics), integrated through the LiveDesign enterprise informatics environment. The company also co-develops proprietary therapeutics (SGR-1505, SGR-3515) and earns milestone/royalty revenue from collaborations with major pharmaceutical partners.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Schrödinger offers a comprehensive computational molecular discovery platform combining physics-based simulation with AI/ML capabilities. The platform architecture centers on Maestro as the primary user interface, with core computational engines including Glide (docking), FEP+ (free energy calculations), Desmond (molecular dynamics), and Jaguar (quantum mechanics). LiveDesign serves as the enterprise informatics platform enabling collaborative workflows. AI/ML capabilities are delivered through DeepAutoQSAR (automated QSAR modeling), LiveDesign ML, and MS Informatics for materials applications. The platform serves both Life Sciences (drug discovery) and Materials Science sectors, and Schrödinger advances proprietary therapeutics through clinical programs including SGR-1505 (MALT1 inhibitor) and SGR-3515 (Wee1/Myt1 inhibitor) in Phase 1 trials.

Product and service13 records
1Maestro
CategoryMolecular Modeling Platform
Description

The primary graphical user interface for Schr\u00f6dinger's molecular modeling suite, providing comprehensive access to all computational tools for molecular discovery and design across life sciences and materials science applications. Targeted at computational chemists, medicinal chemists, and materials scientists.

2Glide
CategoryMolecular Docking
Description

Ligand-receptor molecular docking solution for virtual screening and binding mode prediction using extra-precision scoring to predict binding affinities and identify promising drug candidates. Used by pharmaceutical discovery teams for hit identification.

3FEP+ (Free Energy Perturbation)
CategoryFree Energy Calculations
Description

High-performance free energy calculation engine enabling accurate prediction of binding affinities and ranking of molecular candidates. Used for lead optimization in drug discovery programs.

4LiveDesign
CategoryEnterprise Informatics Platform
Description

Enterprise informatics platform providing a digital molecular design lab for collaborative drug discovery, integrating AI models, physics-based calculations, and experimental data across life sciences and materials science. Targets multi-disciplinary research teams in pharmaceutical companies.

5BioLuminate
CategoryBiologics Discovery
Description

Specialized module for biologics drug discovery providing computational tools for antibody design, protein-protein interaction analysis, and developability assessment for large molecule therapeutics. Targets biologics discovery teams.

6DeepAutoQSAR
CategoryMachine Learning for Chemistry
Description

Automated machine learning solution for training and applying predictive QSAR/QSPR models based on molecular structure with automated hyperparameter optimization, ensemble methods, and uncertainty quantification. Used by computational chemists for property prediction.

7Desmond
CategoryMolecular Dynamics Simulation
Description

High-performance molecular dynamics simulation system for modeling organic and bioorganic molecules, enabling simulation of protein-ligand interactions and dynamic behavior of molecular systems. Used by both life science and materials science researchers.

8Jaguar
CategoryQuantum Chemistry
Description

High-performance quantum mechanics package for accurate prediction of molecular structures and properties using density functional theory and ab initio methods. Supports DFT functionals with dispersion corrections, solvent effects modeling, and automated workflows.

9MS LiveDesign
CategoryMaterials Science Informatics
Description

Materials Science version of the LiveDesign enterprise informatics platform for collaborative materials design and optimization. Targets materials science teams in specialty chemicals, energy, and consumer packaged goods.

10MS Informatics
CategoryMaterials Informatics
Description

Materials Science informatics module providing molecular featurization and machine learning tools for organic, organometallic, polymer, formulation, and inorganic materials. Combines physics-based featurization with automated ML workflows for property prediction.

11Modeling Services
CategoryProfessional Services
Description

Expert computational science services leveraging Schr\u00f6dinger's platform to advance research projects through key drug discovery stages, providing a high-velocity entry point to the Schr\u00f6dinger platform. Targeted at biotech and pharma customers needing augmented computational capacity.

12SGR-1505 (MALT1 inhibitor)
CategoryProprietary Clinical Program
Description

Proprietary Phase 1 clinical stage MALT1 protease inhibitor for treatment of relapsed or refractory B-cell lymphomas including chronic lymphocytic leukemia and Waldenstr\u00f6m macroglobulinemia. Received FDA Fast Track Designation and Orphan Drug Designation.

13SGR-3515 (Wee1/Myt1 inhibitor)
CategoryProprietary Clinical Program
Description

Proprietary Phase 1 clinical stage Wee1/Myt1 dual kinase inhibitor for treatment of advanced solid tumors, leveraging synthetic lethality mechanism in cancer cells. Developed using Schr\u00f6dinger's computational platform.

Scale indicator10 records

Each record includes

Type, Value, Description, Source

Partnership13 partners
Strategic tierMajorTypeTechnology or IntegrationAnnounced on2026-06-23
Description

Schrödinger is one of 50+ companies adopting NVIDIA's BioNeMo Agent Toolkit for life sciences AI agents spanning biology, chemistry, genomics, and drug discovery. Leverages NVIDIA's library of life sciences technologies including Nemotron, NemoClaw, and BioNeMo microservices.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-01-09
Description

Schrödinger announced collaboration to integrate Lilly's TuneLab AI platform into Schrödinger's LiveDesign enterprise informatics platform, giving biotech companies priority access to TuneLab workflows. TuneLab uses federated learning to enable privacy-preserving collaboration. Schrödinger is a priority platform partner for TuneLab workflows in the biotech ecosystem.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-01-01
Description

Multi-year agreement for Manas AI to access Schrödinger's physics-based computational drug discovery platform, integrating it with Manas AI's AI 'world model' for identifying diverse molecular binders. Deep integration combining Schrödinger's physics-based methods with Manas AI's machine learning capabilities.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-01-01
Description

Multi-target research collaboration with up to $2.3 billion in potential milestone payments. Novartis collaboration includes multiple undisclosed programs in discovery stage. $150 million upfront payment received.

Strategic tierMajorTypeStrategic or Co-development Partner
Description

Collaboration initiated December 2022 to discover novel medicines against undisclosed CNS targets. Schrödinger received undisclosed upfront payment and is eligible for additional milestones as program progresses.

6Bristol Myers Squibb
Strategic tierMajorTypeStrategic or Co-development Partner
Description

Collaboration on undisclosed program in neurology. Schrödinger is progressing an undisclosed program for evaluation as potential treatment for pulmonary arterial hypertension with Lilly under separate collaboration.

schrodinger.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Multiple collaborations including TYK2 inhibitor (TAK-279, acquired by Takeda with $111.3M distribution to Schrödinger), HPK1 inhibitor in Phase 1/2 for immuno-oncology, and JAK2 inhibitor (AJ1-11095, acquired by Lilly with Ajax acquisition).

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Collaboration on Hsp90 inhibitor design for antifungal applications. Schrödinger holds equity stake in Bright Angel Therapeutics.

Strategic tierMajorTypeTechnology or Integration
Description

Schrödinger is listed as a major enterprise partner using Claude for healthcare and life sciences applications. Partnership enables AI-powered drug discovery workflows leveraging Anthropic's Claude AI platform.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Partnership with UCSF for AI-based drug design as part of computational biology market developments.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Co-founded company in which Schrödinger holds approximately 6% equity. JAK2 inhibitor AJ1-11095 acquired by Lilly for up to $2.3 billion. Schrödinger eligible for milestones and royalties. Collaboration expanded July 2025 with additional JAK target.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Co-founded company in which Schrödinger holds equity stake. Collaborations include GLP-1R selective program for obesity (ACCG-2671 in Phase 1), APJR agonist for pulmonary arterial hypertension, LPA1R for idiopathic pulmonary fibrosis. Schrödinger eligible for milestones and low single-digit royalties.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Collaboration on jointly-developed ammonia synthesis catalyst Neptune demonstrating over 2x ammonia yield of existing catalysts. Pilot demonstrations planned for 2026/27. Also working on more efficient ethylene oxide catalyst.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

OpenEye, owned by Cadence, builds molecular modeling and cheminformatics software (e.g., OMEGA, FRED, ROCS) for drug discovery and is the closest direct competitor to Schrödinger's Maestro/Glide/FEP+ stack for small-molecule computational chemistry.

TypeDirect peer
Description

CCG sells the Molecular Operating Environment (MOE), one of the most widely deployed academic and industrial molecular modeling platforms; directly comparable in target customer, pricing model, and core functionality (docking, QSAR, protein modeling) to Schrödinger.

TypeBroad incumbent
Description

BIOVIA is Dassault Systèmes' life sciences scientific software suite covering molecular simulation, biologics, lab informatics, and regulatory; broad incumbent with overlapping capabilities (Discovery Studio, Materials Studio) competing with Schrödinger's life sciences and materials portfolios.

TypeBroad incumbent
Description

Certara is a public biosimulation and drug development technology company (Phoenix, Simcyp, Synchrogenix); sells adjacent drug discovery and regulatory software plus services to the same pharmaceutical/biotech customer base as Schrödinger.

TypeDirect peer
Description

Dotmatics provides an enterprise scientific informatics platform (e.g., Studies, Geneious, SnapGene) for R&D workflows; competes with LiveDesign in collaborative drug discovery informatics and has been aggressively bundling cheminformatics capabilities.

TypeEmerging player
Description

Recursion combines high-throughput wet-lab experimentation with AI/ML to drive drug discovery; overlaps with Schrödinger's pipeline-cofounder model and AI-driven discovery narrative but takes a data-first rather than physics-first approach.

TypeEmerging player
Description

Insitro uses ML on large-scale biological data to discover therapeutics, with strategic pharma partnerships (Lilly, Bristol Myers); competes for the same enterprise AI-for-drug-discovery mindshare and partnership dollars that drive Schrödinger's drug discovery revenue.

8Isomorphic Labs
TypeEmerging player
Description

Alphabet-owned Isomorphic Labs is building an AI-first drug discovery engine founded by DeepMind's protein-structure team; an emerging AI-native peer whose AlphaFold-anchored approach could compete with Schrödinger's physics-based methods for new partner deals.

TypeEmerging player
Description

Exscientia pioneered AI-driven small molecule design and operates a hybrid AI + pharma partnership model; competes for both pipeline collaboration economics and the broader "AI for drug discovery" narrative that Schrödinger is leaning into with Bunsen and NVIDIA integrations.

TypeEmerging player
Description

Atomwise applies structure-based AI (AtomNet) and partners with pharma on hit discovery; a relevant emerging peer in the virtual screening and AI-drug-discovery category overlapping with Schrödinger's Glide/DeepAutoQSAR workflows.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers7 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
Yes

Docs URL, Description

Integration3 records

Each record includes

Title, Type, Description, Source

AI capability10 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature11 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles12 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance5 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds9 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors12 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment11 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Schrödinger

Computational Drug Discovery Softwareschrodinger.com

Schr\u00f6dinger provides a physics-based computational molecular discovery platform combining quantum mechanics, molecular dynamics, and machine learning to accelerate drug discovery and materials science for pharmaceutical, biotechnology, academic, and materials industry customers, supplemented by equity stakes in co-founded therapeutic programs.

What Schrödinger does

Schr\u00f6dinger (NASDAQ:SDGR) is a computational molecular discovery software company founded in 1990 and headquartered in New York, with approximately 800 employees across 15 global locations. The company operates a dual business model. First, it licenses a physics-based computational platform that combines quantum mechanics (Jaguar), molecular dynamics (Desmond), molecular docking (Glide), free energy perturbation (FEP+), and proprietary force fields (OPLS4/OPLS3e) with machine learning capabilities (DeepAutoQSAR, LiveDesign ML, generative De Novo Design). The platform is delivered through Maestro (the GUI) and LiveDesign (enterprise informatics), and is transitioning from on-premise licensing to hosted cloud subscriptions with a target of 75% hosted mix within three years. Second, the company pursues co-founded drug discovery programs and strategic collaborations with major pharmaceutical companies, holding equity stakes in entities including Nimbus Therapeutics, Morphic Therapeutic (acquired by Lilly 2024), Ajax Therapeutics (acquired by Lilly 2026 for up to $2.3 billion), Structure Therapeutics, and Copernic Catalysts.

The platform serves three primary customer segments: pharmaceutical and biotechnology companies (the dominant segment with names including Eli Lilly, Novartis, Bristol Myers Squibb, Takeda, and Otsuka), academic research institutions, and materials science companies (specialty chemicals, electronics, energy). FY2025 total revenue was $255.9 million, with software revenue of $199.5 million (+10.6% YoY) and drug discovery revenue of $56.4 million (more than doubled YoY). The software business sells through direct enterprise field sales with annual contract value (ACV) as the key metric; 2026 software ACV guidance is $218-228 million, implying 10-15% growth. Drug discovery revenue flows from milestone and royalty payments on partnered programs, with cumulative potential milestone exposure estimated at approximately $5 billion across the collaboration portfolio.

The company's proprietary clinical pipeline includes SGR-1505 (MALT1 inhibitor with FDA Fast Track and Orphan Drug Designations for B-cell malignancies, Phase 1) and SGR-3515 (Wee1/Myt1 dual kinase inhibitor for solid tumors, Phase 1). Recent strategic moves include a multi-target Novartis collaboration worth up to $2.3 billion in potential milestones (2025), integration of Eli Lilly's TuneLab AI platform into LiveDesign (January 2026), a multi-year platform agreement with AI-native biotech Manas AI (January 2026), adoption of NVIDIA's BioNeMo Agent Toolkit (June 2026), and the planned summer 2026 launch of Bunsen, an agentic AI co-scientist system. As of January 2026, the company's valuation was approximately $4.74 billion with $402.3 million in cash and equivalents at year-end 2025.

Schrödinger firmographics

Firmographics
Name
Schrödinger
Legal name
Schrödinger, Inc.
Website
https://schrodinger.com
Company type
Public
Founded year
1990
Operating status
Operating
Headcount range
501–1,000 employees
Short description
Schr\u00f6dinger provides a physics-based computational molecular discovery platform combining quantum mechanics, molecular dynamics, and machine learning to accelerate drug discovery and materials science for pharmaceutical, biotechnology, academic, and materials industry customers, supplemented by equity stakes in co-founded therapeutic programs.
Ownership category
akta.pro rank

Schrödinger industry classification

Industry
Product category
Computational Drug Discovery Software
NAICS
Software Publishers (5132), Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Services-Commercial Physical & Biological Research (8731), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAIALAA
Drug Discovery (Target ID/Validation & Hit Discovery)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHDAGAEAB
Pharmaceutical & Biotech R&D Simulation (drug discovery, protein/ligand)
Hardware, Technology & Telecom/Quantum Computing/Quantum Simulation & Digital Twins
SECONDARYHLAAAIAL
Library & Diversity Generation Platforms (display libraries, DNA-encoded libraries for biologics, variant libraries)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • Computational drug discovery
  • Molecular simulation software
  • Pharmaceutical research platforms
  • Materials science modeling
  • Quantum chemistry software

Where Schrödinger is headquartered

Location

Headquarters

HQ city
New York
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Schrödinger business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Marketing or Sales, Operations, Infrastructure

Revenue model

  1. Software Licensing: Recurring software licenses for computational molecular discovery platform. Schrödinger is transitioning from on-premise to hosted (cloud-based) software licensing model, targeting 75% migration within three years. Software revenue was $199.5 million in FY2025, growing 10.6% year-over-year.
  2. Drug Discovery Collaborations: Milestone payments and collaboration revenue from drug discovery programs. Drug discovery revenue doubled to $56.4 million in FY2025. Includes partnerships with Lilly, Novartis, Bristol Myers Squibb, Otsuka, and others, with potential milestones up to $5 billion cumulative across portfolio.
  3. Strategic Collaborations - Novartis: $150 million upfront payment from Novartis for multi-target research collaboration with up to $2.3 billion in potential milestone payments

Pricing tiers

ModelBillingPrice
SubscriptionAnnualHosted software licensing (primary model)

Go-to-market motion2 records

Distribution channels3 records

Marketing channels5 records

Schrödinger product offering

Product offering

Core offering

Schrödinger develops and licenses a physics-based computational molecular discovery platform combining quantum mechanics, molecular dynamics, and machine learning to accelerate drug discovery and materials science research. The platform centers on Maestro as the user interface, with computational engines including Glide (docking), FEP+ (free energy perturbation), Desmond (molecular dynamics), and Jaguar (quantum mechanics), integrated through the LiveDesign enterprise informatics environment. The company also co-develops proprietary therapeutics (SGR-1505, SGR-3515) and earns milestone/royalty revenue from collaborations with major pharmaceutical partners.

Product overview

Schrödinger offers a comprehensive computational molecular discovery platform combining physics-based simulation with AI/ML capabilities. The platform architecture centers on Maestro as the primary user interface, with core computational engines including Glide (docking), FEP+ (free energy calculations), Desmond (molecular dynamics), and Jaguar (quantum mechanics). LiveDesign serves as the enterprise informatics platform enabling collaborative workflows. AI/ML capabilities are delivered through DeepAutoQSAR (automated QSAR modeling), LiveDesign ML, and MS Informatics for materials applications. The platform serves both Life Sciences (drug discovery) and Materials Science sectors, and Schrödinger advances proprietary therapeutics through clinical programs including SGR-1505 (MALT1 inhibitor) and SGR-3515 (Wee1/Myt1 inhibitor) in Phase 1 trials.

Differentiator

Problem solved

Functional benefit

Products and services

  • Maestro The primary graphical user interface for Schr\u00f6dinger's molecular modeling suite, providing comprehensive access to all computational tools for molecular discovery and design across life sciences and materials science applications. Targeted at computational chemists, medicinal chemists, and materials scientists.
  • Glide Ligand-receptor molecular docking solution for virtual screening and binding mode prediction using extra-precision scoring to predict binding affinities and identify promising drug candidates. Used by pharmaceutical discovery teams for hit identification.
  • FEP+ (Free Energy Perturbation) High-performance free energy calculation engine enabling accurate prediction of binding affinities and ranking of molecular candidates. Used for lead optimization in drug discovery programs.
  • LiveDesign Enterprise informatics platform providing a digital molecular design lab for collaborative drug discovery, integrating AI models, physics-based calculations, and experimental data across life sciences and materials science. Targets multi-disciplinary research teams in pharmaceutical companies.
  • BioLuminate Specialized module for biologics drug discovery providing computational tools for antibody design, protein-protein interaction analysis, and developability assessment for large molecule therapeutics. Targets biologics discovery teams.
  • DeepAutoQSAR Automated machine learning solution for training and applying predictive QSAR/QSPR models based on molecular structure with automated hyperparameter optimization, ensemble methods, and uncertainty quantification. Used by computational chemists for property prediction.
  • Desmond High-performance molecular dynamics simulation system for modeling organic and bioorganic molecules, enabling simulation of protein-ligand interactions and dynamic behavior of molecular systems. Used by both life science and materials science researchers.
  • Jaguar High-performance quantum mechanics package for accurate prediction of molecular structures and properties using density functional theory and ab initio methods. Supports DFT functionals with dispersion corrections, solvent effects modeling, and automated workflows.
  • MS LiveDesign Materials Science version of the LiveDesign enterprise informatics platform for collaborative materials design and optimization. Targets materials science teams in specialty chemicals, energy, and consumer packaged goods.
  • MS Informatics Materials Science informatics module providing molecular featurization and machine learning tools for organic, organometallic, polymer, formulation, and inorganic materials. Combines physics-based featurization with automated ML workflows for property prediction.
  • Modeling Services Expert computational science services leveraging Schr\u00f6dinger's platform to advance research projects through key drug discovery stages, providing a high-velocity entry point to the Schr\u00f6dinger platform. Targeted at biotech and pharma customers needing augmented computational capacity.
  • SGR-1505 (MALT1 inhibitor) Proprietary Phase 1 clinical stage MALT1 protease inhibitor for treatment of relapsed or refractory B-cell lymphomas including chronic lymphocytic leukemia and Waldenstr\u00f6m macroglobulinemia. Received FDA Fast Track Designation and Orphan Drug Designation.
  • SGR-3515 (Wee1/Myt1 inhibitor) Proprietary Phase 1 clinical stage Wee1/Myt1 dual kinase inhibitor for treatment of advanced solid tumors, leveraging synthetic lethality mechanism in cancer cells. Developed using Schr\u00f6dinger's computational platform.

Companies that use Schrödinger

Customer profile

Named customers7 records

Segments3 records

Ideal customer profiles4 records

Schrödinger technology and API

Technology

Technology focussed Yes

API detail

Has API
Yes
API docs
API detail

Core technology

AI maturity

App detail

Integration3 records

AI capability10 records

Feature11 records

Schrödinger partnerships and signals

Strategic signal

Partnerships

13 partnerships are on record, tiered major, core and minor.

  • NVIDIAmajorTechnology or Integration · 23 June 2026Schrödinger is one of 50+ companies adopting NVIDIA's BioNeMo Agent Toolkit for life sciences AI agents spanning biology, chemistry, genomics, and drug discovery. Leverages NVIDIA's library of life sciences technologies including Nemotron, NemoClaw, and BioNeMo microservices.
  • Eli LillycoreStrategic or Co-development Partner · 9 January 2026Schrödinger announced collaboration to integrate Lilly's TuneLab AI platform into Schrödinger's LiveDesign enterprise informatics platform, giving biotech companies priority access to TuneLab workflows. TuneLab uses federated learning to enable privacy-preserving collaboration. Schrödinger is a priority platform partner for TuneLab workflows in the biotech ecosystem.
  • Manas AIcoreStrategic or Co-development Partner · 1 January 2026Multi-year agreement for Manas AI to access Schrödinger's physics-based computational drug discovery platform, integrating it with Manas AI's AI 'world model' for identifying diverse molecular binders. Deep integration combining Schrödinger's physics-based methods with Manas AI's machine learning capabilities.
  • NovartiscoreStrategic or Co-development Partner · 1 January 2025Multi-target research collaboration with up to $2.3 billion in potential milestone payments. Novartis collaboration includes multiple undisclosed programs in discovery stage. $150 million upfront payment received.
  • Otsuka PharmaceuticalmajorStrategic or Co-development PartnerCollaboration initiated December 2022 to discover novel medicines against undisclosed CNS targets. Schrödinger received undisclosed upfront payment and is eligible for additional milestones as program progresses.
  • Bristol Myers SquibbmajorStrategic or Co-development PartnerCollaboration on undisclosed program in neurology. Schrödinger is progressing an undisclosed program for evaluation as potential treatment for pulmonary arterial hypertension with Lilly under separate collaboration.
  • Nimbus TherapeuticscoreStrategic or Co-development PartnerMultiple collaborations including TYK2 inhibitor (TAK-279, acquired by Takeda with $111.3M distribution to Schrödinger), HPK1 inhibitor in Phase 1/2 for immuno-oncology, and JAK2 inhibitor (AJ1-11095, acquired by Lilly with Ajax acquisition).
  • Bright Angel TherapeuticsminorStrategic or Co-development PartnerCollaboration on Hsp90 inhibitor design for antifungal applications. Schrödinger holds equity stake in Bright Angel Therapeutics.
  • AnthropicmajorTechnology or IntegrationSchrödinger is listed as a major enterprise partner using Claude for healthcare and life sciences applications. Partnership enables AI-powered drug discovery workflows leveraging Anthropic's Claude AI platform.
  • UCSFminorStrategic or Co-development PartnerPartnership with UCSF for AI-based drug design as part of computational biology market developments.
  • Ajax TherapeuticscoreStrategic or Co-development PartnerCo-founded company in which Schrödinger holds approximately 6% equity. JAK2 inhibitor AJ1-11095 acquired by Lilly for up to $2.3 billion. Schrödinger eligible for milestones and royalties. Collaboration expanded July 2025 with additional JAK target.
  • Structure TherapeuticscoreStrategic or Co-development PartnerCo-founded company in which Schrödinger holds equity stake. Collaborations include GLP-1R selective program for obesity (ACCG-2671 in Phase 1), APJR agonist for pulmonary arterial hypertension, LPA1R for idiopathic pulmonary fibrosis. Schrödinger eligible for milestones and low single-digit royalties.
  • Copernic CatalystsminorStrategic or Co-development PartnerCollaboration on jointly-developed ammonia synthesis catalyst Neptune demonstrating over 2x ammonia yield of existing catalysts. Pilot demonstrations planned for 2026/27. Also working on more efficient ethylene oxide catalyst.

Scale indicators10 records

Recent moves6 records

Expansion highlights6 records

Schrödinger competitors and assessment

Company assessment

Direct peers

  • OpenEye Scientific (Cadence Design Systems): OpenEye, owned by Cadence, builds molecular modeling and cheminformatics software (e.g., OMEGA, FRED, ROCS) for drug discovery and is the closest direct competitor to Schrödinger's Maestro/Glide/FEP+ stack for small-molecule computational chemistry.
  • Chemical Computing Group (CCG / MOE): CCG sells the Molecular Operating Environment (MOE), one of the most widely deployed academic and industrial molecular modeling platforms; directly comparable in target customer, pricing model, and core functionality (docking, QSAR, protein modeling) to Schrödinger.
  • Dotmatics: Dotmatics provides an enterprise scientific informatics platform (e.g., Studies, Geneious, SnapGene) for R&D workflows; competes with LiveDesign in collaborative drug discovery informatics and has been aggressively bundling cheminformatics capabilities.

Broad incumbents

  • Dassault Systèmes BIOVIA: BIOVIA is Dassault Systèmes' life sciences scientific software suite covering molecular simulation, biologics, lab informatics, and regulatory; broad incumbent with overlapping capabilities (Discovery Studio, Materials Studio) competing with Schrödinger's life sciences and materials portfolios.
  • Certara: Certara is a public biosimulation and drug development technology company (Phoenix, Simcyp, Synchrogenix); sells adjacent drug discovery and regulatory software plus services to the same pharmaceutical/biotech customer base as Schrödinger.

Emerging players

  • Recursion Pharmaceuticals: Recursion combines high-throughput wet-lab experimentation with AI/ML to drive drug discovery; overlaps with Schrödinger's pipeline-cofounder model and AI-driven discovery narrative but takes a data-first rather than physics-first approach.
  • Insitro: Insitro uses ML on large-scale biological data to discover therapeutics, with strategic pharma partnerships (Lilly, Bristol Myers); competes for the same enterprise AI-for-drug-discovery mindshare and partnership dollars that drive Schrödinger's drug discovery revenue.
  • Isomorphic Labs: Alphabet-owned Isomorphic Labs is building an AI-first drug discovery engine founded by DeepMind's protein-structure team; an emerging AI-native peer whose AlphaFold-anchored approach could compete with Schrödinger's physics-based methods for new partner deals.
  • Exscientia: Exscientia pioneered AI-driven small molecule design and operates a hybrid AI + pharma partnership model; competes for both pipeline collaboration economics and the broader "AI for drug discovery" narrative that Schrödinger is leaning into with Bunsen and NVIDIA integrations.
  • Atomwise: Atomwise applies structure-based AI (AtomNet) and partners with pharma on hit discovery; a relevant emerging peer in the virtual screening and AI-drug-discovery category overlapping with Schrödinger's Glide/DeepAutoQSAR workflows.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Schrödinger social profiles

Digital presence

Schrödinger compliance and trust

Trust signal

Compliance5 records

Schrödinger financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Schrödinger leadership team

Management profile

Number of profiles

Profiles12 records

Schrödinger funding detail

Funding detail

Funding overview

Funding rounds9 records

Investors12 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Schrödinger M&A and investment

M&A and investment

M&A1 record

Investments11 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Schrödinger

What does Schrödinger do?

Schrödinger develops and licenses a physics-based computational molecular discovery platform combining quantum mechanics, molecular dynamics, and machine learning to accelerate drug discovery and materials science research. The platform centers on Maestro as the user interface, with computational engines including Glide (docking), FEP+ (free energy perturbation), Desmond (molecular dynamics), and Jaguar (quantum mechanics), integrated through the LiveDesign enterprise informatics environment. The company also co-develops proprietary therapeutics (SGR-1505, SGR-3515) and earns milestone/royalty revenue from collaborations with major pharmaceutical partners.

Is Schrödinger a public or private company?

Schrödinger is a public company. It is classified as public and is currently operating.

When was Schrödinger founded?

Schrödinger was founded in 1990. It employs 501 to 1,000 people.

Where is Schrödinger based?

Schrödinger is headquartered in New York, United States, in the North America region.

How does Schrödinger make money?

Three revenue lines are on record. Software Licensing is the primary driver. The others are drug Discovery Collaborations and strategic Collaborations - Novartis.

Who are Schrödinger's main competitors?

Direct peers on record are OpenEye Scientific (Cadence Design Systems), Chemical Computing Group (CCG / MOE) and Dotmatics. Broad incumbents are Dassault Systèmes BIOVIA and Certara. Emerging players are Recursion Pharmaceuticals, Insitro, Isomorphic Labs, Exscientia and Atomwise.

Does Schrödinger have an API?

Yes. Schrödinger provides a Python API that allows developers to programmatically interact with Schrödinger software, enabling automation and integration of molecular modeling workflows into custom applications. Developer documentation is at www.schrodinger.com/python-api.

What industry is Schrödinger in?

Schrödinger's product category is Computational Drug Discovery Software. Its primary akta.pro industry code is HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization, with a secondary code of HLAIALAA, Drug Discovery (Target ID/Validation & Hit Discovery). Its NAICS code is 5132 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
36krOverseas AI for Science (AI4S) Top 30 List: Leading Players Transforming Cutting-Edge Scientific Discoveries into Commercial Business ValueTide AI ranked 30 overseas AI4S companies across materials, AI pharmaceuticals, and scientific intelligence, highlighting Schrödinger's 2025 revenue of $255.9 million and SandboxAQ's $450 million Series E. The list also includes Quantinuum's IPO and CuspAI's $450 million Series B, with prospects tied to clinical trials and commercialization.YahooSchrödinger (SDGR) Stock Could Be Undervalued On Its 67% RunSchrödinger's stock has risen 67.4% over the past year, trading at $29.53. Its latest twelve-month free cash flow was a negative $118.33 million, with projections showing near-term losses before recovery. The DCF model suggests intrinsic value exceeds current price, but future cash flows remain uncertain.MarketBeatSchrodinger Eyes Growth From AI Assistant Bunsen and Hosted Software ShiftSchrodinger's CFO said annual contract value will grow 12-17% to $198 million this year, citing growth across pharma, life sciences, and materials science. The AI assistant Bunsen remains in beta, with monetization via throughput-based licensing. The company targets a 75% hosted software share by 2028.Simply Wall StIs Revenue Growth Altering The Investment Case For Schrödinger (SDGR)?Schrödinger reported Q3 2026 revenue of $64.49 million and a net loss of $37.71 million. Over nine months, revenue reached $181.97 million, with a net loss of $91.76 million. Analysts forecast 12.9% annual revenue growth, expecting 2029 revenue of $387.5 million and earnings of $29.6 million.Seeking AlphaSchrödinger, Inc. (SDGR) Presents at 2026 UBS Global Healthcare Conference TranscriptSchrödinger presented at the 2026 UBS Global Healthcare Conference, with CFO Richie Jain and CTO Kenneth Lorton speaking. The company describes itself as a computational platform for molecular discovery, monetized through software licensing, and noted as one of the best-performing stocks over the last three months.Investing.comSchrödinger at UBS Global Healthcare Conference: ai push gains tractionSchrödinger outlined its AI-driven drug discovery strategy at the UBS Global Healthcare Conference, highlighting Bunsen, a physics-first tool for molecular discovery. The company expects annual contract value to grow 12-17% in 2024 from a $198 million base, with a target of 75% hosted deployment by 2028.American Banking and Market NewsCalamos Advisors LLC Makes New Investment in Schrodinger, Inc. $SDGRCalamos Advisors acquired a new stake in Schrodinger, buying 60,036 shares valued at about $1.86 million in Q3. The firm now holds 0.08% of the company, while other institutional investors also adjusted their positions. Analysts rate the stock a Hold with an average target price of $26.67.Defense WorldCritical Analysis: Schrodinger (NASDAQ:SDGR) versus Health In Tech (NASDAQ:HIT)Health In Tech and Schrodinger are compared on valuation, earnings, and analyst ratings. Health In Tech beats Schrodinger on 11 of 15 factors, with a consensus price target of $3.50 versus $26.67. Schrodinger trades at a lower P/E ratio, but Health In Tech has higher earnings.Simply Wall StSchrödinger (SDGR) Raises Its 2026 Outlook, Is The Upside Already Priced In?Schrödinger raised its 2026 outlook after Q3 results, citing software adoption and AI therapeutics progress. The stock rose 60% year-to-date, but Simply Wall St's narrative fair value of $25.86 suggests overvaluation, while its DCF model values it at $42.76, implying undervaluation.Seeking AlphaSchrödinger outlines 2026 ACV of $222M-$232M while raising drug discovery revenue to $75M-$85M (NASDAQ:SDGR)Schrödinger reported Q3 2026 annual contract value (ACV) of $222M-$232M, up 17% or 24% excluding contribution. Drug discovery revenue rose to $75M-$85M, reflecting sustained commercial momentum. Management cited progress toward long-range goals.